PDL1 expression is an independent prognostic factor in localized GIST
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PDL1 expression is an independent prognostic factor in localized GIST
Authors
Keywords
-
Journal
OncoImmunology
Volume 4, Issue 5, Pages e1002729
Publisher
Informa UK Limited
Online
2015-05-21
DOI
10.1080/2162402x.2014.1002729
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Unvalidated antibodies and misleading results
- (2014) David Rimm et al. BREAST CANCER RESEARCH AND TREATMENT
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer
- (2014) François Bertucci et al. CANCER LETTERS
- Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST
- (2014) A. Wozniak et al. CLINICAL CANCER RESEARCH
- In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
- (2014) K. A. Schalper et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy
- (2014) Kim A Reiss et al. Immunotherapy
- PD-L1 Expression Is Increased in a Subset of Basal Type Breast Cancer Cells
- (2014) Hatem Soliman et al. PLoS One
- Programmed Cell Death Ligand 1 Expression in Osteosarcoma
- (2014) J. K. Shen et al. Cancer Immunology Research
- Trial Watch
- (2014) Fernando Aranda et al. OncoImmunology
- Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
- (2013) S. Rusakiewicz et al. CANCER RESEARCH
- Immunotherapy and the concept of a clinical cure
- (2013) Alexander M.M. Eggermont et al. EUROPEAN JOURNAL OF CANCER
- Clinical impact of programmed cell death ligand 1 expression in colorectal cancer
- (2013) Raoul A. Droeser et al. EUROPEAN JOURNAL OF CANCER
- Drug of the year: Programmed Death-1 receptor/Programmed Death-1 Ligand-1 receptor monoclonal antibodies
- (2013) Caroline Robert et al. EUROPEAN JOURNAL OF CANCER
- Programmed death ligand-1 expression in non-small cell lung cancer
- (2013) Vamsidhar Velcheti et al. LABORATORY INVESTIGATION
- GSTT1 Copy Number Gain and ZNF Overexpression Are Predictors of Poor Response to Imatinib in Gastrointestinal Stromal Tumors
- (2013) Eui Jin Lee et al. PLoS One
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- PD-L1 Expression in the Merkel Cell Carcinoma Microenvironment: Association with Inflammation, Merkel Cell Polyomavirus, and Overall Survival
- (2013) E. J. Lipson et al. Cancer Immunology Research
- Blood Neutrophil-to-Lymphocyte Ratio is Prognostic in Gastrointestinal Stromal Tumor
- (2012) Daniel R. Perez et al. ANNALS OF SURGICAL ONCOLOGY
- Genomic Grade Index predicts postoperative clinical outcome of GIST
- (2012) F Bertucci et al. BRITISH JOURNAL OF CANCER
- One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor
- (2012) Heikki Joensuu et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting PD-1/PD-L1 interactions for cancer immunotherapy
- (2012) Laurence Zitvogel et al. OncoImmunology
- Natural History of Imatinib-naive GISTs
- (2011) Sabrina Rossi et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Navigating Risk Stratification Systems for the Management of Patients With GIST
- (2011) Shreyaskumar Patel ANNALS OF SURGICAL ONCOLOGY
- The Management of Gastrointestinal Stromal Tumors: A Model for Targeted and Multidisciplinary Therapy of Malignancy
- (2011) Heikki Joensuu et al. Annual Review of Medicine
- inSilicoDb: an R/Bioconductor package for accessing human Affymetrix expert-curated datasets from GEO
- (2011) J. Taminau et al. BIOINFORMATICS
- Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors
- (2011) P. Lagarde et al. CLINICAL CANCER RESEARCH
- Kinome expression profiling and prognosis of basal breast cancers
- (2011) Renaud Sabatier et al. Molecular Cancer
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
- (2011) Nicolas F Delahaye et al. NATURE MEDICINE
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
- (2011) Vinod P Balachandran et al. NATURE MEDICINE
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells
- (2011) S. Amarnath et al. Science Translational Medicine
- Overall survival and PD-L1 expression in metastasized malignant melanoma
- (2010) Jules Gadiot et al. CANCER
- The GIST paradigm: lessons for other kinase-driven cancers
- (2010) Cristina R Antonescu JOURNAL OF PATHOLOGY
- A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number
- (2010) Annalisa Astolfi et al. LABORATORY INVESTIGATION
- Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial
- (2010) Axel Le Cesne et al. LANCET ONCOLOGY
- A pathway-based classification of human breast cancer
- (2010) M. L. Gatza et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KITmutations and expression
- (2009) Jerzy Ostrowski et al. BMC CANCER
- Natural Killer Cell IFN- Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients
- (2009) C. Menard et al. CANCER RESEARCH
- Cell Cycle/Apoptosis Molecule Expression Correlates with Imatinib Response in Patients with Advanced Gastrointestinal Stromal Tumors
- (2009) S. Romeo et al. CLINICAL CANCER RESEARCH
- Immune cells in primary gastrointestinal stromal tumors
- (2009) Silke Cameron et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
- (2009) Ronald P DeMatteo et al. LANCET
- Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis
- (2009) Jason S Gold et al. LANCET ONCOLOGY
- FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy
- (2008) Hazem Ghebeh et al. BMC CANCER
- Distinct Gene Expression–Defined Classes of Gastrointestinal Stromal Tumor
- (2008) Umio Yamaguchi et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search